<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have shown that diaspirin cross-linked <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (DCLHb, 10 g/dL) decreases <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and the resultant injury in a dose-dependent manner, requiring large volumes of DCLHb for maximum efficacy </plain></SENT>
<SENT sid="1" pm="."><plain>We assessed the effect of a more concentrated (20 g/dL) and more hyperoncotic preparation of DCLHb on <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> volume </plain></SENT>
<SENT sid="2" pm="."><plain>Immediately after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, rats were randomized to one of the following groups: Control, hematocrit not manipulated; 10/Hb, hematocrit decreased to 30% with 10% DCLHb (oncotic pressure 43 mm Hg); 7.5/Alb, hematocrit decreased to 30% with 7.5% albumin (oncotic pressure 43 mm Hg); 20/Hb, the same dose of DCLHb (20%, oncotic pressure 129 mm Hg) as the 10/HB group (half the volume); or 15/Alb, the same dose of albumin (15%, oncotic pressure 130 mm Hg) as the 7.5/Alb group half the volume) </plain></SENT>
<SENT sid="3" pm="."><plain>After 90 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, 72 h of reperfusion was allowed </plain></SENT>
<SENT sid="4" pm="."><plain>Infarction volume (mm3, mean +/- sd) was less in the DCLHb groups (10/Hb = 79 +/- 17; 20/HB = 51 +/- 14) than the oncotically matched albumin groups (7.5/Alb = 124 +/- 21; 15/Alb = 85 +/- 18) and the Control group (135 +/- 17) (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>These data indicate that in this model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, DCLHb decreases ischemic brain injury more effectively than albumin, and that a hyperoncotic preparation of DCLHb is preferable </plain></SENT>
</text></document>